Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 129 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 9 Gy Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

NCT03317158
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Durvalumab (Cohort 1-3), External Beam Radiotherapy (EBRT), Bacillus Calmette-Guérin (BCG), Gemcitabine, Docetaxel, Tremelimumab, Durvalumab (Cohort 4/5), To be determined, Intravesical NAI (Cohorts 6-7), Subcutaneous NAI (Cohort 8)
Drug · Radiation · Biological + 1 more
Lead sponsor
Noah Hahn, M.D.
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Indianapolis, Indiana • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 31, 2026, 5:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases

NCT01421017
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Interventions
Radiation, Imiquimod, Cyclophosphamide
Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 31, 2026, 5:28 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma

NCT03921008
View directory record Official record
Conditions
Cutaneous Angiosarcoma
Interventions
Paclitaxel, Radiation therapy, Research blood draw
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 31, 2026, 5:28 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer

NCT04997018
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 31, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)

NCT00343083
View directory record Official record
Conditions
Cancer of Head and Neck
Interventions
Erbitux, Paclitaxel & Carboplatin, Radiation
Drug · Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 31, 2026, 5:28 AM EDT
Recruiting Not applicable Interventional

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

NCT04221893
View directory record Official record
Conditions
Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Stage IV Adenocarcinoma of the Gastroesophageal Junction, Stage IVA Esophageal Adenocarcinoma, Stage IVA Esophageal Squamous Cell Carcinoma, Stage IVA Gastric Cancer, Stage IVA Adenocarcinoma of the Gastroesophageal Junction, Stage IVB Esophageal Adenocarcinoma, Stage IVB Esophageal Squamous Cell Carcinoma, Stage IVB Gastric Cancer, Stage IVB Gastroesophageal Junction Adenocarcinoma, Metastatic Anal Canal Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Small Intestinal Carcinoma, Pancreatobiliary Carcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Anal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Radiation Therapy (RT)
Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
San Francisco, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 31, 2026, 5:28 AM EDT
Terminated Phase 2 Interventional Results available

Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma

NCT02394665
View directory record Official record
Conditions
Glioblastoma
Interventions
Intensity Modulated Radiation Therapy, Temozolomide, Functional Assessment of Cancer Therapy-Brain (FACT-Br), Stereotactic Radiosurgery Boost, Simultaneous Integrated Boost, 3D MRSI
Radiation · Drug · Behavioral + 1 more
Lead sponsor
University of Miami
Other
Eligibility
19 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Oct 31, 2026, 5:28 AM EDT
Active, not recruiting Phase 2 Interventional

Preop fSRS for Resectable Brain Metastases

NCT05267587
View directory record Official record
Conditions
Brain Metastases, Brain Lesion
Interventions
Hypofractionated Stereotactic Radiosurgery
Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 31, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas

NCT01118377
View directory record Official record
Conditions
Brainstem Glioma
Interventions
Capecitabine, Radiation therapy
Drug · Radiation
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 31, 2026, 5:28 AM EDT
Completed Phase 2 Interventional

Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer

NCT00449020
View directory record Official record
Conditions
Lung Cancer
Interventions
Carboplatin, Docetaxel, irinotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 31, 2026, 5:28 AM EDT
Not yet recruiting Phase 1 Interventional

Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma

NCT07335380
View directory record Official record
Conditions
Oral Cavity Squamous Cell Carcinoma
Interventions
Chemotherapy, Lattice Radiotherapy (LRT)
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 31, 2026, 5:28 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer

NCT01230866
View directory record Official record
Conditions
Prostate Cancer
Interventions
Proton Radiation Hypofractionation, Proton Radiation Standard Fractionation
Radiation
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
Phoenix, Arizona • Warrenville, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 31, 2026, 5:28 AM EDT
Completed Phase 1 Interventional

Single Session Spine Stereotactic Radiosurgery in Metastatic Epidural Spinal Cord Compression

NCT01256554
View directory record Official record
Conditions
Metastatic Epidural Spinal Cord Compression
Interventions
Stereotactic Radiosurgery (SSRS), Questionnaires
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 31, 2026, 5:28 AM EDT
Completed Phase 1 Interventional

Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

NCT02709226
View directory record Official record
Conditions
Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
Interventions
Radiation
Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 31, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

NCT03311555
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Androgen deprivation, Salvage radiation therapy, Docetaxel
Drug · Radiation
Lead sponsor
Andrew J. Armstrong, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Omaha, Nebraska • New York, New York • Cary, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 31, 2026, 5:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer

NCT02643498
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Stereotactic Body Radiotherapy (SBRT)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 31, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

NCT00571662
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease, Peripheral T-cell Lymphoma
Interventions
Pentostatin, Total-body irradiation (TBI), Cyclosporine A (CsA), Mycophenolate Mofetil (MMF), G-CSF
Drug · Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 31, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer

NCT00081289
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Radiation Therapy, Capecitabine 1650 mg/m^2/day, Capecitabine 1200 mg/m^2/day, Irinotecan, Oxaliplatin, Surgery, Folinic Acid, Fluorouracil
Radiation · Drug · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
5
States / cities
Sacramento, California • Miami, Florida • Harvey, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 31, 2026, 5:28 AM EDT
Withdrawn Phase 2 Interventional

SABR for T1-2a N1 NSCLC

NCT03321760
View directory record Official record
Conditions
Lung Cancer
Interventions
Stereotactic Ablative Radiation Therapy (SABR)
Radiation
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 31, 2026, 5:28 AM EDT
Recruiting Phase 3 Interventional

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

NCT01492972
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation, Androgen Suppression Therapy
Radiation · Drug
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older · Male only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
4
States / cities
Scottsdale, Arizona • Warrenville, Illinois • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 31, 2026, 5:28 AM EDT
Withdrawn Phase 2 Interventional

A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

NCT07414992
View directory record Official record
Conditions
Bladder Urothelial Carcinoma
Interventions
Stereotactic body radiotherapy, Cemiplimab, Cemiplimab and Fianlimab, Radical cystectomy
Radiation · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 31, 2026, 5:28 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma

NCT01020812
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Hepatobiliary Neoplasm, Liver Carcinoma
Interventions
TACE, SBRT
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 31, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

NCT00490529
View directory record Official record
Conditions
Lymphoma, Mantle-Cell
Interventions
CpG-MCL vaccine, PF-3512676, Vaccine-primed T-cells, Autologous hematopoietic stem cell transplant (HSCT), Rituximab, Standard induction chemotherapy, Cyclophosphamide, Filgrastim
Biological · Procedure · Drug
Lead sponsor
Ronald Levy
Other
Eligibility
21 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 31, 2026, 5:28 AM EDT
Completed Not applicable Interventional Results available

Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer

NCT00694577
View directory record Official record
Conditions
Ductal Breast Cancer
Interventions
Partial Breast Irradiation using 32 Gy / 8 fractions, Partial Breast Irradiation using 36 Gy / 9 fractions, Partial Breast Irradiation using 40 Gy /10 fractions
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 31, 2026, 5:28 AM EDT